Compare Northrop Grumman Corporation (NOC) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Northrop Grumman Corporation vs Sanofi SA — how do they compare? Northrop Grumman Corporation trades at $519.79 (market cap $73.24B), while Sanofi SA trades at $43.12 (market cap $103.41B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.65%). Which is the better fit depends on your goals.
| NOC | SNY | |
|---|---|---|
Market Cap | $73.24B | $103.41B |
Sector | Industrials | Health |
52-Week High | $768.02 | $52.34 |
52-Week Low | $496.02 | $41.33 |
Enterprise Value | $87.23B | $123.44B |
Dividend Yield | 1.92% | 5.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Northrop Grumman (NOC) trades at $518.58, up 0.7% with a bullish technical oscillator signal despite bearish moving averages. The company shows strong fundamentals with consistent earnings beats, 10.48% net margin, and record $105 billion backlog. Recent news highlights defense spending growth and successful technology tests, while institutional ownership increased significantly in Q2 2026.
Outlook remains positive with 57% analyst buy ratings and $618.43 consensus target offering 19% upside. Key risks include defense budget volatility and execution challenges on large contracts. Revenue growth acceleration to 10.48% margin by 2026 supports valuation at reasonable 16.37 P/E multiple.
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
